• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Altamira Therapeutics Ltd. - Common Shares
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

7.620 -0.360 (-4.51%)
Delayed Quote Updated: 4:00 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 457,638
Open 7.820
Bid (Size) 7.600 (200)
Ask (Size) 7.620 (5,000)
Prev. Close 7.980
Today's Range 7.560 - 8.056
52wk Range 7.560 - 17.15
Shares Outstanding 21,055,392
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Revenue Miss and In-Line EPS as Shares Slip After Hours ↗
November 16, 2026
Via Chartmill
News headline image
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026
November 16, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire

Performance

52-Week Range 55.6% below 52-week high
7.620
7.5652W Low 17.1552W High
1 Week 31.3% below 1-week high
7.561W Low 11.091W High

Enanta Pharmaceuticals, Inc. - Common Stock (ENTA) traded between $7.56 and $17.15 over the past 52 weeks and last traded at $7.62, 55.6% below its 52-week high. Over the past week it ranged between $7.56 and $11.09.

Past 12 Months
-28.6%
-32.6%
-43.4%
-45.4%
-47.2%
-37.2%
1W -$3.05
1M -$3.69
3M -$5.85
6M -$6.33
YTD -$6.80
1Y -$4.51

ENTA was -37.2% over the past year, -45.4% over six months, -47.2% year to date, -28.6% in the last week.

12 Months vs Market
ENTA
-37.2%
DIA
+5.0%
SPY
+5.7%
QQQ
+3.9%
IWM
+12.0%

Over the past 12 months ENTA returned -37.2% versus DIA (Dow) +5.0%, SPY (S&P 500) +5.7%, QQQ (Nasdaq 100) +3.9% and IWM (Russell 2000) +12.0%.

Volume & Liquidity 1.60× 3-mo avg
Today 457,638 3-mo avg 286.6K
1W
559.3K
1M
326.3K
3M
286.6K
6M
248.1K
YTD
222.3K
1Y
238.3K

ENTA most recently traded 457,638 shares against a 3-month average daily volume of 286.6K.

More News

Read More
News headline image
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
November 04, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership
October 28, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
ENANTA PHARMACEUTICALS INC (NASDAQ:ENTA) Q2 Results: Narrower Losses, Clinical Milestones in Focus ↗
May 11, 2026
Via Chartmill
Enanta Pharmaceuticals (NASDAQ:ENTA) Beats Q1 Estimates, Reaffirms Cash Runway Into 2029 ↗
February 09, 2026
Via Chartmill
News headline image
Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)
October 26, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
October 13, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Participate in September Investor Conferences
September 01, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
August 10, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
June 23, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
June 18, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗
May 30, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
May 28, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
May 11, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
May 04, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
April 13, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
April 07, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
March 30, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
March 03, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
February 10, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
February 09, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
January 08, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Reports Mixed Q4 and Full-Year 2025 Results ↗
November 17, 2025
Via Chartmill

Frequently Asked Questions

Is Enanta Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Enanta Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Enanta Pharmaceuticals, Inc. - Common Stock trade on?
Enanta Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Enanta Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Enanta Pharmaceuticals, Inc. - Common Stock is ENTA on the Nasdaq Stock Market
What is the current price of Enanta Pharmaceuticals, Inc. - Common Stock?
The current price of Enanta Pharmaceuticals, Inc. - Common Stock is 7.620
When was Enanta Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Enanta Pharmaceuticals, Inc. - Common Stock was at 11/20/26 04:00 PM ET
What is the market capitalization of Enanta Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Enanta Pharmaceuticals, Inc. - Common Stock is 160.44M
How many shares of Enanta Pharmaceuticals, Inc. - Common Stock are outstanding?
Enanta Pharmaceuticals, Inc. - Common Stock has 160M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap